Shire PLC (SHPG) Stock Rating Reaffirmed by Shore Capital
Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating restated by investment analysts at Shore Capital in a research report issued on Saturday.
Several other brokerages have also issued reports on SHPG. Piper Jaffray Cos. set a $201.00 price target on Shire PLC and gave the company a “hold” rating in a research note on Saturday, October 1st. Leerink Swann reissued a “buy” rating on shares of Shire PLC in a research note on Saturday, October 1st. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Royal Bank Of Canada reissued an “outperform” rating on shares of Shire PLC in a research note on Wednesday, June 15th. Finally, RBC Capital Markets reissued an “outperform” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Five analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. Shire PLC has a consensus rating of “Buy” and a consensus price target of $232.75.
Shire PLC (NASDAQ:SHPG) opened at 194.50 on Friday. The company has a 50 day moving average of $195.56 and a 200 day moving average of $187.04. The company has a market capitalization of $57.93 billion, a PE ratio of 40.42 and a beta of 1.16. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/shire-plc-shpg-stock-rating-reaffirmed-by-shore-capital-2.html
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The business had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.28 billion. During the same period in the prior year, the business posted $2.63 earnings per share. The firm’s revenue was up 55.9% on a year-over-year basis. On average, analysts predict that Shire PLC will post $12.92 earnings per share for the current fiscal year.
The firm also recently disclosed a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were paid a $0.139 dividend. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC increased its position in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the period. Canal Insurance CO acquired a new position in shares of Shire PLC during the second quarter worth about $102,000. FTB Advisors Inc. increased its position in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares during the period. Duncker Streett & Co. Inc. acquired a new position in shares of Shire PLC during the second quarter worth about $111,000. Finally, Ropes Wealth Advisors LLC acquired a new position in shares of Shire PLC during the second quarter worth about $114,000. Hedge funds and other institutional investors own 24.26% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.